hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-25. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Nycomed, a Swiss drug company which manufactures Actovegin, claims it can be used for circulation and nutrition disturbances, skin grafting, burns, and wound-healing impairment. Actovegin has also been used as a performance enhancer. It has been investigated for use in treatment of polyneuropathy in diabetes, and for stroke. One study found that when tissues suffer from hypoxia caused circulation abnormalities, Actovegin helps capillaries improve circulation by enhancing the neogenic mechanism in blood vessels. Anaphylactic shock has been observed in at least one patient treated with actovegin. There are reports suggesting that Actovegin have ergogenic ability, however one small trial found no apparent benefit from short-term use. Two studies certified Actovegin to have an anti-inflammatory effect. One of the two studies certified Actovegin to reduce Progressive muscular atrophy-induced inflammation in human cells. Another study certified Actovegin to have a positive impact on the growth of muscle cells.
Nickel-78 is one of the element's heaviest known isotopes. With 28 protons and 50 neutrons, nickel-78 is doubly magic, resulting in much greater nuclear binding energy and stability despite a lopsided neutron-proton ratio. Its half-life is 122 ± 5.1 milliseconds. Due to its magic neutron number, 78Ni is believed to have an important role in supernova nucleosynthesis of elements heavier than iron. 78Ni, along with N = 50 isotones 79Cu and 80Zn, are thought to constitute a waiting point in the r-process, where further neutron capture is delayed by the shell gap and a buildup of isotopes around A = 80 results.
Newer varieties are now pending regulatory approval in the US which are designed to work rapidly, but retain the same genetic structure as regular human insulin. Short-acting insulin includes regular insulin, which begins working within 30 minutes and is active about 5 to 8 hours. Intermediate-acting insulin includes NPH insulin, which begins working in 1 to 3 hours and is active for 16 to 24 hours. Long-acting insulin includes the analogues glargine U100 and detemir, each of which begins working within 1 to 2 hours and continues to be active, without major peaks or dips, for about 24 hours, although this varies in many individuals. Ultra-long acting insulin includes the analogues insulin glargine U300 and degludec, which begin working within 30 to 90 minutes and continues to be active for greater than 24 hours. Newer long-acting insulins, like insulin icodec and insulin efsitora alfa, are designed for once-weekly use. Studies show they provide similar blood sugar control to daily insulins, with a comparable risk of hypoglycemia, while offering a simpler dosing routine. Combination insulin products combine fast- and short-acting insulin with a longer-acting insulin like NPH insulin. The combination products begin to work with the shorter-acting insulin (5–15 minutes for fast-acting, and 30 minutes for short-acting), and remain active for 16–24 hours. There are several variations with different proportions of the mixed insulins (e.g., Novolog Mix 70/30 contains 70% aspart protamine [akin to NPH], and 30% aspart).
==== September 2008 ==== On 1 September 2008, journalist of Nezavisimaya Gazeta wrote: "As early as 6 August I saw our army in full combat readiness near the Georgian border." On 2 September 2008, it was reported that several soldiers' mothers had sent letter to Commissioner for Human Rights in Perm Krai. One mother wrote that on 3 August his son said his unit might be deployed to the border. Another mother said that his son told her on 9 August that his unit was sent to South Ossetia on the evening of 7 August. On 11 September 2008, Yulia Latynina wrote that journalists who were sent in advance to cover the war reported on 6 August 2008 that they have seen "58th Army in full combat readiness on the other [Georgian] side of the Roki tunnel". On 15 September 2008, Novaya Gazeta reported that the South Ossetian soldier had told journalist that after the end of "Kavkaz 2008" exercises 80 tanks remained in South Ossetia. Journalist had also spoken with several Russian soldiers during her visit and they said they had been based in South Ossetia for a month, since 6 August 2008. The journalist noted that the Russian forces did not officially participate in the battle for Tskhinvali on 8 August, apparently waiting until the Georgian troops take the city, so later they could destroy both Tskhinvali and the Georgians. The construction of the road from Tskhinvali to Akhalgori had started 2 years ago.
Sources: en.wikipedia.org
== Patents == U.S. patent 2,163,754 was issued on June 27, 1939 – Ticket dispensing machine. U.S. patent D132,182 was issued on April 28, 1942 – Design for air conditioning unit. U.S. patent 2,336,735 was issued on December 14, 1943 – Removable cooling units for compartments. U.S. patent 2,337,164 was issued on December 21, 1943 – Means for automatically stopping and starting gas engines. U.S. patent 2,376,968 was issued on May 29, 1945 – Two-cycle gas engine. U.S. patent 2,417,253 was issued on March 11, 1947 – Two-cycle gas engine. U.S. patent 2,475,841 was issued on July 12, 1949 – Automatic refrigeration system for long-haul trucks. U.S. patent 2,475,842 was issued on July 12, 1949 – Starter generator. U.S. patent 2,475,843 was issued on July 12, 1949 – Means operated by a starter generator for cooling a gas engine. U.S. patent 2,477,377 was issued on July 26, 1949 – Means for thermostatically operating gas engines. U.S. patent 2,504,841 was issued on April 18, 1950 – Rotary compressor. U.S. patent 2,509,099 was issued on May 23, 1950 – System for controlling operation of refrigeration units. U.S. patent D159,209 was issued on July 4, 1950 – Design for air conditioning unit. U.S. patent 2,523,273 was issued on September 26, 1950 – Engine actuated ventilating system. U.S. patent 2,526,874 was issued on October 24, 1950 – Apparatus for heating or cooling atmosphere within an enclosure. U.S. patent 2,535,682 was issued on December 26, 1950 – Prefabricated refrigerator construction. U.S. patent 2,581,956 was issued on January 8, 1952 – Refrigeration control device. U.S.
Okara, from the Japanese 雪花菜(おから), is known as 雪花菜 xuěhuācài, in Chinese, lit. "snowflake vegetable"; 豆腐渣, dòufuzhā, also Chinese, lit. "tofu sediment/residue"; and 콩비지, kongbiji, in Korean). Sometimes known in the west as "soy pulp" or "tofu lees", okara is a tofu by-product consisting of the fiber, protein, and starch left over when soy milk has been extracted from ground soaked soybeans. It is often used as animal feed in most tofu-producing cultures, but also has other uses in Japanese and Korean cuisines, such as in the Korean stew kongbiji jjigae (콩비지찌개). It is also an ingredient for vegetarian burgers in many Western nations. In Japan, it is used to make ice cream.
== Synthetic history == Vanillin was first isolated as a relatively pure substance in 1858 by Théodore Nicolas Gobley, who obtained it by evaporating a vanilla extract to dryness and recrystallizing the resulting solids from hot water. In 1874, the German scientists Ferdinand Tiemann and Wilhelm Haarmann deduced its chemical structure, at the same time finding a synthesis for vanillin from coniferin, a glucoside of coniferyl alcohol found in pine bark. Tiemann and Haarmann founded a company Haarmann and Reimer (now part of Symrise) and started the first industrial production of vanillin using their process (now known as the Reimer–Tiemann reaction) in Holzminden, Germany. In 1876, Karl Reimer synthesized vanillin (2) from guaiacol (1).
Estrogens can be produced in the brain from steroid precursors. As antioxidants, they have been found to have neuroprotective function. The positive and negative feedback loops of the menstrual cycle involve ovarian estradiol as the link to the hypothalamic-pituitary system to regulate gonadotropins. Estrogen is considered to play a significant role in women's mental health, with links suggested between the hormone level, mood and well-being. Sudden drops or fluctuations in, or long periods of sustained low levels of estrogen may be correlated with significant mood-lowering. Clinical recovery from depression postpartum, perimenopause, and postmenopause was shown to be effective after levels of estrogen were stabilized and/or restored. The volumes of sexually dimorphic brain structures in transgender women were found to change and approximate typical female brain structures when exposed to estrogen concomitantly with androgen deprivation over a period of months, suggesting that estrogen and/or androgens have a significant part to play in sex differentiation of the brain, both prenatally and later in life. There is also evidence the programming of adult male sexual behavior in many vertebrates is largely dependent on estradiol produced during prenatal life and early infancy. It is not yet known whether this process plays a significant role in human sexual behavior, although evidence from other mammals tends to indicate a connection.
== Adverse effects == The most common potential side effects when using tadalafil are headache, stomach discomfort or pain, indigestion, burping, acid reflux, back pain, myalgia (pain in limbs and extremities), flushing, hypertension (or uncommonly hypotension), and stuffy/runny nose. Also common are dizziness, peripheral edema, fatigue, and urinary or respiratory tract infection; both diarrhea and constipation have been reported. Diarrhea was reported more frequently in patients 65 or older than in younger subjects. These side effects reflect the ability of PDE5 inhibition to cause vasodilation (causing blood vessels to widen) and usually resolve after a few hours.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.